Neuphoria Therapeutics Inc. NEUP
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Neuphoria Therapeutics Inc. (NEUP) is a healthcare company listed in the US with a market value of about $14M. In fiscal year 2026 it had revenue of $1M and net income of -$13M, a net margin of -1145.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -67%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Neuphoria Therapeutics
Neuphoria Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $14609 in 2023 to $1M in 2026, growth of about 331.6% a year. It was profitable in 3 of the last 7 years in our data.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1M | $16M | — | $14609 | — | — | — |
| Net income | -$13M | -$369632 | -$15M | -$21M | $628352 | $669049 | $941330 |
| Free cash flow | — | — | — | — | -$15M | -$6M | -$3M |
| EPS (diluted) | $-2.49 | $-0.07 | $-2.86 | $-3.95 | $0.12 | $0.12 | $0.17 |
| Net margin | -1145.7% | -2.4% | — | -146400.0% | — | — | — |
| ROIC | -66.2% | -4.7% | -100.4% | -97.7% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Neuphoria Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Neuphoria Therapeutics pay a dividend?
Not currently.
Is Neuphoria Therapeutics a good stock to buy?
We do not give buy or sell advice. Neuphoria Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.